融合基因检测在AML-M_2与AML-M_3鉴别诊断中的价值及其临床意义

Detection of fusion gene in differential diagnosis of patients with AML-M_2 and AML-M_3 and its clinical significance

本研究对临床形态学上难以分型的急性非淋巴细胞白血病在染色体核型分析及免疫表型分析的基础上,采用逆转录聚合酶链反应(RT-PCR)检测了AML-M_3的PML-RARα和AML-M_2的AML_1-Eto两种融合基因的mRNA,并对该两种亚型的鉴别诊断及其实用意义作了初步探讨。

Eleven patients with unclassified acute nonlymphoblastic leukemia defined according to French-American-British (FAB) classifi-cation were investigated. Using nested reverse transcription-polymerase chain reaction (RT-PCR) assay after analyzing the im-munophenotvpe and karyotypic abnormality, the PML/RARα and AML1-Eto fusion gene transcripts were detected in all patients. These results showed that 10 cases were positive, 2 of them were without chromosomal abnormality, whereas l case with hybrid a-cute leukemia (HAL) was negitive. The study suggested that the detection of fusion gene was a more accurate and sensitive indicator in the diagnosis. It greatly contributed to the establishment of chemotherapy, the evaluation of prognosis and the monitoring of mini-mal residual disease (MRD) in acute nonlymphoblastic leukemia patients.